Related Experiment Video

Updated: Mar 8, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.7K

A Review on SIRtuins in Diabetes

R Aditya, A Ravi Kiran, D Sai Varma

  • 1School of Health Sciences, University of Tasmania, Launceston, Tasmania, Australia.

Current Pharmaceutical Design
|January 28, 2017
PubMed
Abstract

Insights

SIRT1 activators show promise for type-2 diabetes treatment by improving insulin secretion and glucose metabolism. This review explores SIRT1

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type-2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia.
  • Sirtuin 1 (SIRT1), a key metabolic regulator, is a therapeutic target for T2DM, with activators currently in clinical trials.
  • Understanding SIRT1's role in metabolic pathways is crucial for developing effective T2DM treatments.

Purpose of the Study:

  • To review recent advances and challenges in the field of SIRT1 modulation for metabolic diseases.
  • To discuss the physiological regulation of SIRT1 activity and its therapeutic potential.
  • To explore novel drug design strategies targeting SIRT1 for diabetes and age-related diseases.

Main Methods:

  • Review of literature on sirtuin biology, focusing on SIRT1's role in insulin secretion, cell cycle, and apoptosis.
  • Analysis of computational and biological methods for SIRT1 drug discovery.
  • Discussion of physiological regulation mechanisms of SIRT1 activity.

Main Results:

  • SIRT1 activation positively regulates insulin secretion and enhances glucose uptake and utilization.
  • Advanced computational and biological methods are being developed to specifically target SIRT1.
  • Decade-long research highlights the complexity and potential of SIRT1 modulation in metabolic regulation.

Conclusions:

  • SIRT1 activators represent a promising therapeutic strategy for type-2 diabetes.
  • Further research into SIRT1 biology and targeted drug design is essential for optimized treatments.
  • SIRT1 modulation may offer benefits for various age-related human diseases beyond diabetes.
Keywords:
SIRT1SIRT1 activatorType II diabetes mellitusclinical trialsinsulin secretionresveratrol

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

703

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.0K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.8K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827